Eliem Therapeutics, a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, agreed to acquire Tenet Medicines, a development-stage private biotechnology company. Financial terms were not disclosed. “The Eliem board of directors has conducted a thorough review of strategic alternatives, and we believe the transaction we are announcing today with Tenet presents a compelling opportunity for our stockholders. We believe TNT119 represents a promising clinical asset across multiple autoimmune diseases targeting markets where there is a need for improved treatment options,” Andrew Levin, Eliem Therapeutics Executive Chairman.